IP Library Granted Patent US 7,816,393
Granted Patent B2
US 7,816,393 · App. 12/535,642 · Granted Oct 19, 2010

Isoindoline compounds and methods of their use

Assignee: Celgene Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,816,393
App. No.
12/535,642
Granted
Oct 19, 2010
Kind
B2
Abstract

Novel isoindoline compounds are disclosed. Methods of treating, preventing and/or managing cancer, diseases and disorders associated with, or characterized by, undesired angiogenesis, and diseases and disorders mediated by PDE 4, using the compounds are also disclosed.

Claims (7)

1. A compound of formula:

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R 1 and R 2 , independently of the other, is hydroxyl or NH—Z;

R 3 is hydrogen;

Z is hydrogen or aryl; and

n is 0, 1 or 2.

2. A pharmaceutical composition comprising a compound of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: CELGENE CORPORATION
To: AMGEN INC.
Reel/Frame 051181/0038 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2011
From: MULLER, GEORGE W.; MAN, HON-WAH
To: CELGENE CORPORATION
Reel/Frame 025878/0257 →
Continuity (2)
Division 1207032200 · Feb 15, 2008
Related Publication 20090291991A1 · Nov 26, 2009